Showing 4431-4440 of 7028 results for "".
- Can IL-33 Blockade Ease Severe Poison Ivy Itch? Mouse Study Says Maybehttps://practicaldermatology.com/news/can-il-33-blockers-ease-severe-poison-ivy-itch/2458382/Blocking interleukin 33 (IL-33) may put the brakes on the uncontrollable itch caused by poison ivy, poison sumac, poison oak and even mango trees, according to a mouse study conducted by scientists at Duke Health in Durham, NC, and Zhejiang Chinese Medical University in China. The r
- Bob Rhatigan Joins ALASTIN Skincare's Board of Directorshttps://practicaldermatology.com/news/bob-rhatigan-joins-alastin-skincares-board-of-directors/2458384/Bob Rhatigan is joining ALASTIN Skincare™, Inc’s Board of Directors effective December 2016. Mr. Rhatigan most recently served as President and Chief Operating Officer at Alphaeon Corporation. Prior to this, he spent 17 years at Allergan In
- Scleroderma Treatment Breakthrough? New Study Hints At Way To Slow Skin Fibrosishttps://practicaldermatology.com/news/scleroderma-treatment-breakthrough-new-study-suggests-way-to-slow-skin-fibrosis/2458387/New and ongoing research at Hospital for Special Surgery (HSS) in New York City has identified a possible mechanism behind the fibrosis that occurs in scleroderma – a mechanism that may one day lead to a treatment for the disease. The findings appear in the
- Brenton L. Saunders is Allergan's New Chairman of the Boardhttps://practicaldermatology.com/news/brenton-l-saunders-is-allergans-new-chairman-of-the-board/2458389/Brenton L. Saunders is Allergan’s new Chairman of the Board, the company reports. Effective today, Saunders will replace Paul Bisaro, who served as Executive Chairman since July 1, 2014. Bisaro will remain a member of the Allergan Board of
- Avon Chooses Greenwich, CT Dermatologist to Champion ANEW Brandhttps://practicaldermatology.com/news/avon-chooses-greenwich-conn-dermatologist-to-champion-anew-brand/2458390/Kim Nichols, MD, is now Avon’s new consulting dermatologist. In her role, the Greenwich, Conn.-based dermatologist will help to educate Avon Representatives on the technology behind the
- Biosim Update: Pfizer to Begin Shipping INFLECTRA in Late November 2016https://practicaldermatology.com/news/biosim-update-pfizer-to-begin-shipping-inflectra-in-late-november-2016/2458400/Pfizer Inc. will begin shipment of INFLECTRA (infliximab-dyyb) for injection, a biosimilar of REMICADE1 (infliximab) to wholesalers in the United States in late November 2016. INFLECTRA will be the first biosimilar mono
- Sweden Greenlights Allergan's Double Chin-Melting BELKYRA®https://practicaldermatology.com/news/sweden-greenlights-allergans-double-chin-melting-belkyra/2458404/The Swedish Medical Products Agency has greenlighted Allergan’s BELKYRA® (deoxycholic acid) for submental fat reduction. BELKYRA® is already licensed in Canada, Australia, Iceland, Hungary, Austria, Lithuania, Estonia, Latvia, Romania, Bulgaria and Norway, as well
- Meet the Newest Filler on the Block: Biologica Technologies' Allofill™https://practicaldermatology.com/news/meet-the-newest-filler-on-the-block-biologica-technologies-allofill/2458412/A newly launched off-the-shelf fat-derived filler may provide the long-lasting results associated with fat grafting plus the convenience of other ready-to-use injectables. Allofill is Biologica Technologi
- Beauty Business to Go Green with New Master Class, Institutehttps://practicaldermatology.com/news/beauty-business-to-go-green-with-new-master-class-institute/2458421/The newly formed National Beauty Science Institute (NBSI) aims to promote sustainability, authenticity and green energy in the beauty business. The group will hold its first Master Class in April 2017 to educate students and consumers on the science and sustainability of beauty – a
- Regeneron and Sanofi's Dupilumab Biologics License Application Accepted for Priority Review by FDAhttps://practicaldermatology.com/news/regeneron-and-sanofis-dupilumab-biologics-license-application-accepted-for-priority-review-by-fda/2458423/The FDA has accepted for priority review the Biologics License Application (BLA) for dupilumab from Regeneron Pharmaceuticals, Inc. and Sanofi for the treatment of adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD). The application has been given a Prescription